GlassScriptPhysician profile
Kirk M Olson
NPI 1396753497
$3,113.87
in general payments reported to CMS, 2019-2025
16 companies · $860 in 2025
The $860 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $176 · 2023: $868 · 2024: $1,211 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.12 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.20 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $558.09 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $231.72 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $215.88 | 2023-2025 | Rexulti, Brintellix |
| Alkermes, INC. | $205.12 | 2023-2025 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $202.20 | 2023-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Axsome Therapeutics, INC. | $175.64 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.36 | 2023-2024 | Caplyta |
| Livanova USA, INC. | $112.30 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Takeda Pharmaceuticals U.S.A., INC. | $92.27 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $55.19 | 2023-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $53.46 | 2024 | Ingrezza |
| Sage Therapeutics, LLC | $37.97 | 2024-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $34.28 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $16.97 | 2025 | Qelbree |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $16.22 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.